Pirtobrutinib

Introduction Overview

Generic Name

pirtobrutinib

Brand Name

Jaypirca

Dosage Form

tablets (50 mg, 100 mg)

Drug Class

BTK inhibitors

Pharmacokinetics

Absorption:
Pirtobrutinib, administered orally as Jaypirca tablets, demonstrates adequate bioavailability following single and repeated dosing. Although specific absorption rates and Tmax values are not publicly detailed, the drug is designed to exert systemic therapeutic effects with once-daily dosing, indicative of suitable oral absorption kinetics. Food does not significantly affect its absorption, allowing the medication to be taken with or without food, providing flexibility in dosing schedules.

Distribution:
Pirtobrutinib exhibits a distribution profile consistent with kinase inhibitors targeting hematologic malignancies. While exact volume of distribution data is limited, its high selectivity for Bruton's tyrosine kinase (BTK) suggests efficient penetration into lymphoid tissues where malignant B-cells reside. Protein binding data is not extensively reported; however, as an oral small molecule, it is expected to have moderate protein binding facilitating systemic exposure.

Metabolism:
Pirtobrutinib is extensively metabolized predominantly by cytochrome P450 3A4 (CYP3A4) enzymes in the liver. This metabolic pathway accounts for its susceptibility to interactions with strong CYP3A inhibitors and inducers. Metabolism leads to inactive metabolites excreted in urine and feces. The drug's design as a non-covalent reversible BTK inhibitor reduces potential for irreversible enzyme binding, impacting its metabolism and pharmacodynamics.

Elimination:
The elimination half-life of pirtobrutinib has been reported to support once-daily dosing, though precise half-life values are variable and depend on hepatic function. The drug and its metabolites are excreted primarily via fecal routes with some renal elimination. Patients with hepatic or renal impairment may require careful monitoring due to altered elimination kinetics. No accumulation was seen with repeated dosing, indicating balanced elimination and dosing regimens.

The pharmacokinetic profile supports the clinical use of Jaypirca in adult patients, providing sufficient systemic exposure to inhibit BTK activity while maintaining manageable safety parameters. The metabolic involvement of CYP3A highlights the necessity for awareness of potential drug-drug interactions.

Dosage Forms

Available Dosage Forms:
Jaypirca is available as oral tablets in strengths of 50 mg and 100 mg. These film-coated tablets contain the active ingredient pirtobrutinib and a combination of inactive excipients such as croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. The film coating includes FD & C Blue #2, hypromellose, titanium dioxide, and triacetin, which aid in stability and patient compliance.

Dosages for Adults and Adolescents:
The standard recommended dose for adult patients diagnosed with relapsed or refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL) is 200 mg orally once daily. This dosage is administered continuously until disease progression or unacceptable toxicity occurs. Jaypirca has not been established for safety and efficacy in pediatric patients; thus, adolescent dosing is not recommended.

Specific Patient Populations:
Dose adjustments or special precautions are not specifically outlined for populations with renal or hepatic impairment; however, due to hepatic metabolism via CYP3A enzymes, patients with liver dysfunction should be closely monitored. Because of limited data on pediatric safety and efficacy, Jaypirca is currently indicated only for adult patients. Females of reproductive potential must use effective contraception given the drug’s potential for fetal harm, and breastfeeding is discouraged during treatment.

Clinical guidelines recommend adherence to the prescribed 200 mg once daily dosing, and tablets should be swallowed whole with water, without crushing or chewing, permitting administration with or without food. Frequent blood monitoring is essential to assess for toxicities such as cytopenias and liver function abnormalities during therapy.

Mechanism Of Action

Jaypirca (pirtobrutinib) exerts its antineoplastic effects through selective inhibition of Bruton's tyrosine kinase (BTK), a critical enzyme in the B-cell receptor (BCR) signaling pathway. BTK is a non-receptor tyrosine kinase expressed primarily in B-cells and plays an essential role in regulating B-cell development, activation, proliferation, and survival. Aberrant activation of BTK has been implicated in the pathogenesis and progression of various B-cell malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

Unlike earlier BTK inhibitors which covalently and irreversibly bind BTK at the C481 residue, Jaypirca is a non-covalent, reversible BTK inhibitor. This mechanism allows it to bind selectively and potently even in the presence of mutations conferring resistance to covalent inhibitors (e.g., C481S mutation). Jaypirca’s binding affinity is approximately 300 times more selective for BTK over other kinases, minimizing off-target effects and improving safety profiles.

At the molecular level, Jaypirca inhibits BTK phosphorylation and downstream signaling by preventing BTK activation, blocking critical cascades including PLCγ2 activation, calcium mobilization, and NF-κB signaling pathways. This blockade impedes B-cell receptor-mediated proliferation and survival signals crucial in malignant B-cell growth. Consequently, malignant B-cells undergo apoptosis or growth arrest due to the loss of survival cues.

Clinical studies demonstrate that Jaypirca effectively reduces tumor burden in patients with CLL, SLL, and MCL, including those previously treated with covalent BTK inhibitors who developed resistance. Its reversible and non-covalent mechanism offers an alternative therapeutic approach, broadening options for treatment-resistant B-cell malignancies. The drug's distinct binding profile and downstream effects show promise in overcoming resistance mechanisms and improving patient outcomes.

Pharmacological Actions

Selective inhibition of Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling.
Non-covalent, reversible binding to BTK, effective even in some mutations resistant to covalent BTK inhibitors.
Inhibition of downstream signaling pathways such as PLCγ2 phosphorylation, calcium mobilization, and NF-kB activation.
Induction of apoptosis and inhibition of proliferation in malignant B cells in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).
Overcomes resistance mechanisms to prior covalent BTK inhibitors by diverse molecular binding.
Exhibits high selectivity for BTK over other kinases, reducing off-target pharmacological activity.
Oral kinase inhibition allowing systemic exposure upon once-daily oral dosing.
Modulation of immune cell function by interrupting pathogenic B-cell survival signals.
Potential reduction in tumor burden and improvement of hematologic malignancy symptoms.
Possible immunosuppressive effects increasing risk of infections due to B-cell inhibition.
Pharmacodynamic effects consistent with blockade of pathological B-cell signaling.
Minimal drug accumulation with repeated administration supporting steady efficacy.
Favorable pharmacokinetic profile that supports flexible dosing with or without food.
Reduction of malignant lymphocyte counts leading to clinical responses in relapsed/refractory hematologic cancers.
Action complementary to BCL-2 inhibitors in combination treatment regimens.

Therapeutic Or Clinical Uses

Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two previous lines of systemic therapy, including a BTK inhibitor.
Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior therapies including both a BTK inhibitor and a BCL-2 inhibitor.
Management of B-cell malignancies resistant to covalent BTK inhibitors due to its non-covalent mechanism of BTK inhibition.
Reduction of tumor burden and disease progression in relapsed/refractory hematologic cancers.
An oral therapeutic option for patients unable to tolerate or refractory to existing BTK inhibitors.
Salvage therapy in recurrent or progressive mantle cell lymphoma and CLL/SLL.
Potential for use in combination regimens due to its targeted kinase inhibitory action.
Use indicated under accelerated FDA approval based on response rates with ongoing confirmatory trials.
Improvement of hematologic parameters and lymphoma-related symptoms in treated populations.
Alternative BTK targeting in patients with mutations conferring ibrutinib and acalabrutinib resistance.
Treatment consideration in patients with relapsed disease despite multiple prior chemotherapies.
Supports targeted molecular therapy approach in chronic lymphoproliferative disorders.
Addresses a significant unmet need for patients with limited therapeutic options post frontline treatments.
Oral administration enhances patient compliance and convenience in outpatient settings.
Use recommended with regular blood monitoring due to risk of hematological and infectious complications.

Side Or Adverse Effects

Bruising (ecchymosis) and increased tendency to bleed.
Generalized fatigue and tiredness.
Diarrhea of varying severity.
Peripheral edema and swelling.
Musculoskeletal discomfort including muscle, joint, and bone pain.
Fever and chills indicative of possible infection.
Respiratory symptoms such as cough with mucus production.
Chest pain and shortness of breath potentially linked to cardiac arrhythmias.
Serious infections including opportunistic infections like Pneumocystis jirovecii pneumonia.
Potential for severe bleeding events including internal hemorrhage.
Hematologic toxicities such as neutropenia, thrombocytopenia, and anemia.
Liver toxicity potentially causing severe liver injury or failure.
Cardiac arrhythmias including atrial fibrillation and atrial flutter.
Allergic reactions presenting as hives, facial swelling, or airway obstruction.
Secondary primary malignancies including skin cancers.

Precautions

Monitor for signs of infection regularly due to immunosuppressive effects.
Closely observe for bleeding manifestations due to increased hemorrhage risk.
Monitor complete blood counts frequently to detect cytopenias early.
Conduct liver function tests prior to and during treatment to identify hepatotoxicity.
Use sun protection (SPF 30 or higher) to minimize risk of skin cancers.
Advise patients on recognizing symptoms of cardiac arrhythmias and seek prompt care.
Avoid abrupt discontinuation without physician consultation to prevent disease flare.
Use effective contraception in females of reproductive potential to prevent fetal harm.
Inform patients about potential drug interactions, especially with CYP3A inhibitors/inducers.
Assess patients' history for bleeding disorders or concurrent anticoagulant use.
Caution in patients with cardiac rhythm abnormalities or uncontrolled hypertension.
Avoid breastfeeding during treatment and for at least one week post therapy.
Evaluate patient suitability in presence of multiple comorbidities or other cancers.
Monitor closely in elderly or patients with reduced hepatic or renal function.
Educate patients on adherence to dosing schedule and management of missed doses.

Warnings

Serious and sometimes fatal infections including bacterial, viral, and fungal etiologies have been reported; consider prophylactic measures especially for high-risk patients.
Severe bleeding events, including life-threatening hemorrhages, necessitate vigilant monitoring for bleeding symptoms.
Significant hematologic abnormalities such as neutropenia, thrombocytopenia, and anemia can occur, requiring frequent laboratory monitoring.
Severe liver injury including potentially fatal hepatotoxicity necessitates regular hepatic function surveillance.
Cardiac arrhythmias including atrial fibrillation and atrial flutter have been observed; patients should be monitored with ECG and clinical assessment.
Increased incidence of secondary primary cancers, including non-melanoma skin cancers, mandates regular skin examinations and sun protection.
Potential fetal harm and teratogenicity require pregnancy exclusion before initiation and effective contraception during and after therapy.
Delayed wound healing and complications around surgeries necessitate careful timing of therapy relative to surgical procedures.
Immunosuppression related to BTK inhibition may increase susceptibility to opportunistic infections.
Use is not established in pediatric populations; safety and efficacy data lacking.
Risk of tumor lysis syndrome in high tumor burden malignancies under treatment.
Recommend prompt medical attention for any signs of allergic reactions or hypersensitivity.
Drug interactions with CYP3A modulators may enhance toxicity or reduce efficacy.
Missed doses require specific management to maintain adequate BTK inhibition and avoid resistance.
Therapy discontinuation should be carefully weighed against disease progression risk.

Contraindication

Known hypersensitivity to pirtobrutinib or any of the inactive components in Jaypirca tablets.
Pregnancy, due to potential for causing fetal harm and teratogenic effects.
Patients with uncontrolled active infections until infection is resolved.
Concurrent use with strong CYP3A inducers or inhibitors that cannot be managed due to risk of altered drug exposure.
Presence of severe hepatic impairment until appropriate safety data is available and monitoring can be assured.
Use in pediatric patients below 18 years due to lack of established safety and efficacy data.
Uncorrected bleeding diathesis or coagulopathy without adequate management.
Active secondary malignancies that require immediate treatment may contraindicate Jaypirca until stable.
Severe cardiac arrhythmias uncontrolled or unmonitored during treatment.
Known hypersensitivity to drugs with similar chemical structure if cross-reactivity is suspected.
Patients who are breastfeeding during treatment and for one week after last dose.
Situations where patient compliance with monitoring and dosing cannot be guaranteed.

Drug Interactions

Strong CYP3A inhibitors (e.g., cobicistat, ritonavir, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin) may increase pirtobrutinib plasma concentrations, enhancing toxicity risk.
Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) may reduce pirtobrutinib plasma concentrations, decreasing therapeutic efficacy.
Moderate CYP3A inducers such as bosentan, dabrafenib, efavirenz, primidone, and phenobarbital can similarly reduce drug exposure.
Co-administration with grapefruit juice may unpredictably alter pirtobrutinib levels due to CYP3A interactions.
Combination with anticoagulants or antiplatelet agents may increase bleeding risk.
Concomitant use with other immunosuppressive therapies may potentiate infection risk.
Potential interactions with drugs that prolong QT interval require careful cardiac monitoring.
CYP3A modulators may necessitate dose adjustments or alternative therapies.
Drugs metabolized via CYP pathways may have altered concentrations when given with Jaypirca.
Herbal supplements inducing or inhibiting CYP3A enzymes may impact pirtobrutinib activity.
Monitoring required when administered alongside other targeted cancer therapies.
No significant interactions reported with food; administration with or without meals is acceptable.
Avoid abrupt discontinuation of concomitant therapies without medical advice due to risk of adverse interactions.
Comprehensive medication reconciliation recommended before initiating Jaypirca.
Patient education on potential interaction risks and symptoms of toxicity is essential.

Preparations Of The Drug

Oral film-coated tablets containing 50 mg pirtobrutinib per tablet.
Oral film-coated tablets containing 100 mg pirtobrutinib per tablet.
Tablets formulated with excipients including croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide.
Film coating consisting of FD & C Blue #2, hypromellose, titanium dioxide, and triacetin to ensure stability and patient acceptability.
Supplied in child-resistant bottles to enhance safety during storage.
Storage at controlled room temperature of 20°C to 25°C (68°F to 77°F) to maintain drug integrity.
Oral solid dosage form enabling precise dosing and patient adherence.
Manufactured by Eli Lilly and Company with quality assurance standards.
Designed for once-daily oral administration to facilitate outpatient cancer therapy.
Available in blister packs or bottles depending on supply and regional distribution.
Packaging to protect from moisture and light exposure.
Labeling includes dosing instructions, safety warnings, and storage guidelines.
Formulated to ensure consistent bioavailability and therapeutic efficacy.
Excipient profile suitable for most patients without known allergens.
Medication leaflets and patient information provided with packaging for education.